Quote:
Originally Posted by ZucchiniFlower
From another article:
Finding genetic markers for the placebo effect could raise ethical questions about how companies design their clinical trials, Furmark says. For example, "it could be tempting to screen all individuals and ... select only those with [the] nonresponsive phenotype [for the trial]."
Why is that an ethical question? It would be wonderful if one could exclude those that might exhibit a strong placebo effect from the trial. How is that possibly unethical?
http://sciencenow.sciencemag.org/cgi...ll/2008/1202/1 |
ZF,
I'm still somewhat in a fog today so if the logic is off here I'm sorry. But would it be better to just factor in the placebo genes [somehow] and still let those prone to placebo effect have a shot at the treatment? I'm not sure if that even makes sense, but wouldn't it be unethical to eliminate those with the genes from getting a potentially life saving treatment in time? Is that what they are saying?
paula